Comparing overall survival between first generation EGFR-TKIs and chemotherapy in lung cancer patients with Del19/L858R.

Item

http://www.wikidata.org/entity/Q42414610

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Comparing overall survival bet ...... cer patients with Del19/L858R.

@en

Comparing overall survival bet ...... cer patients with Del19/L858R.

@nl

type

Item

label

Comparing overall survival bet ...... cer patients with Del19/L858R.

@en

Comparing overall survival bet ...... cer patients with Del19/L858R.

@nl

prefLabel

Comparing overall survival bet ...... cer patients with Del19/L858R.

@en

Comparing overall survival bet ...... cer patients with Del19/L858R.

@nl

P1476

Comparing overall survival bet ...... cer patients with Del19/L858R.

@en

P2093

Haiyan Tu

http://www.w3.org/2001/XMLSchema#string

Honghong Yan

http://www.w3.org/2001/XMLSchema#string

Jinji Yang

http://www.w3.org/2001/XMLSchema#string

Siyang Liu

http://www.w3.org/2001/XMLSchema#string

Wei Deng

http://www.w3.org/2001/XMLSchema#string

Yilong Wu

http://www.w3.org/2001/XMLSchema#string

Yuanyuan Lei

http://www.w3.org/2001/XMLSchema#string

P2860

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Measuring inconsistency in meta-analyses

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

P304

339-347

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21147/J.ISSN.1000-9604.2016.03.08

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27478319

http://www.w3.org/2001/XMLSchema#string

P932

4949279

http://www.w3.org/2001/XMLSchema#string